Bristol Myers Squibb identifies cause of safety signal in lupus CAR‑T trial

Bristol Myers Squibb's cell therapy division is confronting ongoing safety challenges with its autoimmune CAR‑T program.

The company says it has pinpointed the underlying cause of the safety signal that emerged in a lupus trial, a signal that had raised concerns after a patient death.

Lynelle Hoch noted that the new insight will inform adjustments to the therapy and future trial designs, though the program remains under regulatory scrutiny and its timeline remains uncertain.